中国药品专利商品化研究

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Patent commercialization is the most effective external way to enhance the competitiveness of pharmaceutical companies.By analyzing the commercial data of Chinese granted pharmaceutical patents from 2007 to 2016,it finds that non-enterprise entities are the main R&D bodies of NME and NCE patents.The enterprises are the main R&D bodies of drug incremental innovative patents.The patents owned by the foreign entities have higher commercial value,but more authorized pharmaceutical patents held by the domestic patentee have less commercialization.The division of R&D is unreasonable between domestic non-enterprises entities and enterprises.In order to solve the problems faced by Chinese pharmaceutical R&D bodies in the progress of patents commercialization,the author puts forward some recommendations.The government should guide different domestic R&D entities to carry out specialized division of labor through subjective and objective aspects,further improve the pattern of the patent subsidy and weaken the non-commodity attribute of patent.

Key words： Pharmaceutical Patent Commercialization

Received: 05 February 2018

PACS:

R2-0

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Lichun

Cite this article:

Liu Lichun. Research on Commercialization of Chinese Pharmaceutical Patents[J]. , 2018, 0(12): 96-105.

URL:

http://www.zgkjlt.org.cn/EN/ OR http://www.zgkjlt.org.cn/EN/Y2018/V0/I12/96

[1]TUFTS Center.The study of drug development′s 2016 study[R].2017.
[2]DIMASI J A.New drug innovation and pharmaceutical industry structure:trends in the output of pharmaceutical firms[J].Drug information journal,2000,34(4):1169-1194.
[3]LEVIN R C,KLEVORICK A K,NELSON R R,et al.Appropriating the returns from industrial research and development[J].Brookings papers on economic activity,1987(3):783-831.
[4]MANSFIELD E.Patents and innovation:an empirical study[J].Management science,1986,32(2):173-181.
[5]中国医药企业管理协会,中国化学制药工业协会,中国医药保健品进出口商会,中国外商投资企业协会药品研制和开发行业委员会.构建可持续发展的中国医药创新生态系统[R].2016.
[6]SCHERER F M.Firm size,market structure,opportunity,and the output of patented inventions[J].The American economic review,1965,55(5):1097-1125.
[7]ERNST H.Patent information for strategic technology management[J].World patent information,2003,25(3):233-242.
[8]COHEN W M,NELSON R R,WALSH J P.Protecting their intellectual assets:appropriability conditions and why US manufacturing firms patent(or not)[R].National Bureau of Economic Research,2000.
[9]KANG K,SOHN S Y.Evaluating the patenting activities of pharmaceutical research organizations based on new technology indices[J].Journal of informetrics,2016,10(1):74-81.
[10]ZHAO L,XIANG Y,YI Q.Fuzzy front end patent management and innovation performance:mediating role of patent commercialization and moderating effect of technological lock-in[J].Management decision,2017,55(6):1143-1162.
[11]BANERJEE A,BAKSHI R,SANYAL M K.Valuation of patent:a classification of methodologies[J].Research bulletin,2017,42(4):158-174.
[12]LEHMAN B.The pharmaceutical industry and the patent system[J].International intellectual property institute,2003:1-14.
[13]GALLINI N.Do patents work？Thickets,trolls and antibiotic resistance[J].Canadian journal of economics/revue Canadienne D′économique,2017,50(4):893-926.
[14]DUTTA D K,HORA M.From invention success to commercialization success:technology ventures and the benefits of upstream and downstream supply-chain alliances[J].Journal of small business management,2017,55(2):216-235.
[15]FACHLER A.The need for reform in pharmaceutical protection:the inapplicability of the patent system to the pharmaceutical industry and the recommendation of a shift towards regulatory exclusivities[J].Fordham Intell.Prop.media & Ent.LJ,2013,24(1):1059-1098.
[16]REDDY G B,KADRI H.Local working of patents:law and implementation in India[J].Journal of intellectual property rights,2013,18(1):15-27.
[17]HELEN W H.Bridging the translational gap:collaborative drug development and dispelling the stigma of commercialization[J].Drug discovery today,2016,21(2):299-305.
[18]KHANNA R,GULER I,NERKAR A.Fail often,fail big,and fail fast？Learning from small failures and R&D performance in the pharmaceutical industry[J].Academy of management journal,2016,59(2):436-459.
[19]WAGNER S,WAKEMAN S.What do patent-based measures tell us about product commercialization？Evidence from the pharmaceutical industry[J].Research policy,2016,45(5):1091-1102.
[20]CHRISTIE A F,DENT C,MCINTYRE P,et al.Patents associated with high-cost drugs in Australia[J].PLoS one,2013,8(4):e60812.
[21]周斌,吴晓明.基于抗肿瘤药市场视域下的我国药品自主创新能力浅析[J].中国医药工业杂志,2014,45(9):113-116.
[22]国家知识产权局.2016年中国专利调查数据报告[R].2017.
[23]国家知识产权局规划发展司.2001—2008年我国化学药领域发明专利态势分析[R].专利统计简报,2009,6.